Engagement & Consultation · For Special Interest Organizations & Lobbyists
Bring your concerns to the table
We built the ramps. Tell us where it still pinches.
The NSRA is a finished bill, and its core mechanisms are drafted to be defensible. But it was engineered with exemptions, transition windows, and pre-deprivation due process for the organizations and businesses it affects. If your organization has a stake in a provision, this is an open, on-the-record channel to review those accommodations and submit input.
We would rather hear your concerns now than in a hearing room. Serious, specific input, especially with data, makes the bill better and the record stronger.
What the bill already builds for you
The accommodation architecture
These are not afterthoughts, they are drafted into the statute to prevent shock, protect property rights, and give affected parties a runway.
Small-entity exemptions
Businesses under $10M in revenue and landlords under ten single-family units are expressly exempt. Obligations fall on the largest actors, not Main Street.
Transition & compliance windows
Multi-year runways, e.g., 24–36 months for housing divestiture, phased pharmaceutical compliance, rather than overnight mandates.
Pre-deprivation due process
Statutory notice schedules of 45 / 60 / 180 days (Title XVIII), engineered to Mathews v. Eldridge, plus an ALJ verification warrant before large asset actions.
Market-rate divestiture
Any required sale is arms-length at fair market value, with an independent-appraisal right and Court of Federal Claims review. No forced sale below appraised value.
Licensing, not expropriation
Pharmaceutical enforcement uses a compulsory license, the patent holder keeps title and receives an 8% / 12% / 4% royalty, with just-compensation arbitration. Not a taking.
Cost-floor safety valve
No price cap compels a manufacturer to sell below audited cost; interim relief at cost plus a reasonable margin is available pending audit.
Market-shock throttle
The V_abs absorption throttle caps forced housing divestiture at ≤4.5% of local inventory per quarter, so required sales cannot distort a market.
Severability
Under §205, if a court strikes one title the rest of the Act continues in full force, a challenge to one provision does not jeopardize the others, and it narrows the fight to that provision.
Legal & technical, full audit
Corporate Benefit Audit, scored, by sector
The NSRA is not anti-corporate. It is anti-extraction. This audit scores each sector on net benefit received, counting every exemption, credit, grant, demand expansion, transition rebate, and just-compensation guarantee the bill extends to it, weighed against the costs it bears. Every sector that makes things, employs people, and competes on merit gains. Every sector that profits from wage arbitrage, rent extraction, or financial engineering is restructured, with compensation. That distinction is intentional.
Benefit Scale:
7.0–10 Major net beneficiary
5.0–6.9 Net positive on balance
4.0–4.9 Mixed, gains offset by restructuring
Below 4.0 Net restructured, protections retained
Small Business (<$10M)
9.5/10
Expressly exempt from all Covered Entity obligations. Zero-equity Vanguard Capital grants. Free SBA compliance assistance. Tiered penalty schedules. Domestic content certification at no cost. The most pro-small-business legislation in a generation.
Domestic Manufacturers
8/10
WEA eliminates foreign wage arbitrage advantage. Buy American procurement preferences. Reshoring tax credit (15% accelerated depreciation). SPI Wage Floor Tax Credit (7.5%). $3B semiconductor fund. Corporate rate increase and carbon fee are real costs, offset by stronger domestic demand from BMP and wage floor provisions.
Defense Contractors
5.5/10
SDEC binding efficiency audits expose cost-overrun programs. 95% domestic content is strict. But defense spending is maintained and $500M Vanguard grants fund critical materials manufacturers. Win for lean operators, loss for bloated cost-plus programs.
Large Corps (non-financial)
5/10
Corporate rate 28% (+7pts). SS payroll cap elimination raises employer labor costs on high-wage employees. NIMA (0.18% of gross revenue). Carbon fee. Offset by stronger consumer demand from BMP and infrastructure investment that reduces operational costs. Companies with genuine domestic value chains face higher taxes but a stronger economy.
Big Tech / Data Platforms
5/10
Graduated per-day penalties (Patch J: $500K/day → $2M/day) replace blanket revenue seizure. Judicial order required for structural remedies. $0.02/GB data tariff on model training ingestion. Foreign AI registration and sovereignty audits. Open-Source Compute Pool and semiconductor fund create new markets. Companies with transparent, domestic data practices face manageable compliance. Companies built on uncompensated data extraction face structural disruption.
Banking & Financial Institutions
4/10
FEPSA: 15% surtax on ROE above 12%. FTT: 0.1% on equity/bond trades. Capital flight monitoring with 4-hour ALJ warrant. 200% penalty for quantum migration non-compliance. LBO interest cap eliminates the financial engineering playbook. Community banks and credit unions below $10B are largely exempt, this targets the top tier.
Fossil Fuel & Energy
3.5/10
Carbon fee $40/ton rising to $130/ton by Year 10. Royalty rates increased: onshore 12.5%→18.75%, offshore 18.75%→22%. New 8% hardrock mineral royalty. Transitional industry rebates (75% in Yrs 1-3) and Border Carbon Adjustment provide competitive protection during transition, the bill is designed to price carbon out of the energy mix long-term.
Pharmaceutical Industry
3/10
Automatic patent recapture within 30 days of G7 parity breach. 8% royalty on generics, 12% orphan, 4% PHE. BMP formulary capped at G7 levels. $550B in federal Medicare + Medicaid savings over 10 years ($55B/yr), sourced from PNAS 2024 analysis of full G7 parity for outpatient pharmaceuticals across Canada, France, Germany, Japan, and the UK. Industry loses pricing power in the world's largest pharmaceutical market. Bayh-Dole march-in applies only to taxpayer-funded research, fully private R&D is unaffected.
The NSRA does not eliminate health insurance, it regulates it. BMP covers the individual and small-group market (28M currently uninsured Americans per the bill's own findings), expanding the total covered pool carriers can serve. Large-group, employer-sponsored, and supplemental markets remain fully intact. The regulatory framework is specific: carriers face a 15% overhead/profit ceiling (85% MLR floor) with a 100% levy on retained premium above that ceiling routed to the Health Sovereignty Fund; a $25,000 per-instance automated civil penalty for prohibited prior-authorization denials; and a prior-authorization ban on all BMP-covered services except non-emergency inpatient admissions exceeding 5 days. Carriers accumulating 250+ violations in 12 months face mandatory suspension. Net result: carriers that operate on delivery efficiency gain a fully-covered patient pool and no billing risk. Carriers whose revenue model depends on denial rates and administrative friction face structural compliance costs. The bill targets the overhead, not the industry.
Healthcare Providers
8/10
Hospitals and provider networks are net beneficiaries. BMP closes the uncompensated care gap, hospitals currently absorb an estimated $42B/yr in uncompensated care costs (AHA figure; not stated in the bill) that suppress margins and get cost-shifted to insured patients. Under BMP, every patient carries coverage; bad-debt write-offs collapse and collection rates improve. PE acquisition of hospitals, nursing homes, and rural health systems is prohibited with 48-month divestment windows and just compensation at acquisition cost + Treasury yield. The $1B Vital Systems Transition Reserve pre-funds rural hospital stabilization before enforcement begins. BMP carriers that participate in the top-25% quality tier receive up to a 5% bonus on risk-adjusted rates, providers treating BMP enrollees benefit from those better-capitalized carrier partners. The bill's zero-cost-sharing mandate eliminates one of the primary drivers of delayed care and bad-debt: patients who skip treatment because they can't afford a copay. Independent, nonprofit, and federally qualified health centers benefit most; PE-owned and high-overhead consolidated systems face the steepest compliance investment.
Patch J judicial order requirement + 45/60/180-day notice schedules protect portfolio companies from immediate clawbacks. PE investment in competitive markets unrestricted, restrictions apply to SFR housing only of systems whose failure kills people. Hospitals, nursing homes, 911 dispatch, rural emergency services, and EMS are not investment theses; they are public safety infrastructure. The evidence base is unambiguous: private equity ownership of these systems is correlated with increased mortality, accelerated staff cuts, and destabilized local healthcare markets. The restriction is surgical, not ideological. Outside of Critical Life-Safety Systems: housing portfolio capped at 50 units/MSA, agricultural land concentration capped at 12%. Carried interest taxed as ordinary income. LBO interest deductibility capped. Just compensation at acquisition cost + Treasury yield is provided on all forced divestments, this is not confiscation, it is regulated exit.
REITs / Institutional Real Estate
4.5/10
V_abs 4.5%/quarter orderly divestment schedule + independent appraisal + Penn Central compliance. Managed portfolio wind-down replaces cliff divestment. 50-unit MSA cap applies to SFR only. 20% Rent Extraction Levy on rents above Structural Rent Baseline in concentrated markets. V_abs throttle prevents fire-sale losses. Just compensation at acquisition cost + Treasury yield provided. The business model of institutional single-family housing aggregation is legislated out of existence, with compensation.
The Distinction That Matters: Read the scores as a benefit ledger, not a threat assessment. No sector on this list is destroyed; every restructured sector retains a protected path, statutory exemptions for community banks and small business, just compensation at acquisition cost plus Treasury yield on every forced divestment, transitional rebates and border adjustment for energy, and untouched fully-private R&D for pharmaceutical firms. This bill restructures the financial economy, the part of the corporate world that extracts value from housing, healthcare, data, and financial markets without creating it, and reinvests that value into the productive economy: the part that manufactures, employs, and builds. If your business model survives on merit, the NSRA is the most favorable operating environment in decades. The corporate allies this bill naturally creates, domestic manufacturers, community banks, clean energy companies, domestic healthcare providers, small businesses, represent a durable coalition.
The legal footing
Constitutional grounding: the authority, and your protections
These provisions are drafted to be defensible and, just as important, to protect the parties they affect. Here is the enumerated-powers basis the Act rests on, and the constitutional safeguards built in for you.
The authority the Act rests on
Commerce Clause
Art. I, §8, cl. 3, regulation of interstate commerce and financial markets (housing concentration, financial-sector rules, supply-chain provisions).
Spending Clause
Art. I, §8, cl. 1, conditions attached to federal funds (coverage, household relief, grant programs).
Necessary & Proper
Art. I, §8, cl. 18, the mechanisms that carry the enumerated powers into effect.
General Welfare
The taxing-and-spending power supporting the fiscal and benefit architecture.
The protections built in for you
Fifth Amendment takings
No forced sale below appraised value; market-rate, arms-length divestiture with an independent-appraisal right and Court of Federal Claims review. Compliance is drafted to satisfy the Penn Central three-factor test.
Licensing, not expropriation
Pharmaceutical enforcement is a compulsory license, the patent holder keeps title and receives an 8%/12%/4% royalty with just-compensation arbitration. Not a taking.
Procedural due process
Pre-deprivation notice of 45/60/180 days (Title XVIII), engineered to Mathews v. Eldridge, plus an ALJ verification warrant before large asset actions.
Article III & the jury right
Consistent with SEC v. Jarkesy, civil monetary penalties are adjudicated in an Article III court with the Seventh Amendment jury right preserved; ALJs are limited to temporary, status-quo asset-preservation.
Nondelegation & major questions
Mandatory trigger parameters are fixed by Congress in statute (not delegated open-endedly), supplying an intelligible principle responsive to Gundy and West Virginia v. EPA.
Severability
§205, if a court strikes one title, the rest of the Act continues in full force, with a fallback appropriation protecting first-tier benefits.
Full detail is in the Statement of Constitutional Authority and Title 0 (§002(4)) of the bill. These are the campaign’s positions, not a court’s ruling; specialist and legislative-counsel review are welcomed and pending.
Where we’re settled, and where we want your input
An honest scope for the conversation
Our starting point
- The core fiscal architecture and mechanisms are already complete and stress-tested, so the conversation begins from a solid draft, not a blank page.
- We’re protective of the outcomes people are counting on, lower drug prices, coverage, housing relief, deficit reduction, and flexible on how we get there.
- The constitutional safeguards (due process, market-rate compensation, licensing rather than taking) protect you too, so we’d keep them, while staying open on how they operate.
Open to your input
- Implementation detail and phase-in calibration within a provision.
- Sector-specific transition timing, where you can show a genuine operational constraint.
- Data that improves an estimate or surfaces an unintended effect.
- Drafting that achieves the same outcome with less friction.
In short: we’re committed to the destination and genuinely open on the road. Bring evidence and we’ll engage it seriously, this is a conversation, not an ultimatum.
Good faith, on the record. This channel is for constructive, specific engagement. Input does not bind either party and is not legal advice; substantive submissions may be summarized in a public consultation record. TheAmericanDeal, Inc. is a Wyoming 501(c)(4) civic-education organization; materials here are informational and non-partisan. Statutory parameters cited are the text of the bill; fiscal figures referenced elsewhere are model estimates, scoring pending.